Here are the complete notes with Vancouver references at the end:
Pharmacological Management of Pain
(Opioids | Non-Opioids | Adjuvants | Local Anesthetics)
+ Recent Evidence Pertaining to Physiotherapy
FIRST - UNDERSTAND PAIN BRIEFLY
Pain = an unpleasant sensory and emotional experience associated with actual or potential tissue damage.
Pain travels via:
- Nociceptors → A-delta fibers (fast, sharp) and C-fibers (slow, burning) → Spinal cord (dorsal horn) → Brain
All analgesic drugs target one or more steps in this pathway.
THE WHO ANALGESIC LADDER
A 3-step framework - start at Step 1, move up only if pain is uncontrolled:
STEP 3: Severe Pain
Strong Opioids (Morphine, Oxycodone, Fentanyl)
+ Non-opioid ± Adjuvant
STEP 2: Moderate Pain
Weak Opioids (Tramadol, Codeine)
+ Non-opioid ± Adjuvant
STEP 1: Mild Pain
Non-Opioids (Paracetamol, NSAIDs)
± Adjuvant
Key principle: Use the lowest effective step. Add adjuvants at any step for specific pain types (especially neuropathic).
PART 1 - NON-OPIOID ANALGESICS
What are they?
Drugs that relieve pain without acting on opioid receptors. First choice for most musculoskeletal (MSK) pain.
A. Paracetamol (Acetaminophen)
Simple explanation: Works in the brain/CNS to reduce pain and fever. Does NOT reduce peripheral inflammation or swelling.
Mechanism: Inhibits COX enzymes in the CNS; may also activate cannabinoid pathways via the AM404 metabolite (exact mechanism still debated).
Key facts:
- Mild to moderate pain
- Safe for stomach (unlike NSAIDs)
- Maximum dose: 4 g/day in adults; 2 g/day in elderly
- Overdose = acute liver failure - most dangerous effect
Physio context: First-line for osteoarthritis pain; used when anti-inflammatory effect is not needed.
B. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Simple explanation: Block the COX enzyme that makes prostaglandins - chemicals that cause pain, fever, and swelling. Block prostaglandins = less pain + less inflammation.
Mechanism: Inhibit COX-1 and COX-2 → reduced prostaglandin synthesis
| Drug | Notes |
|---|
| Ibuprofen | Most common OTC NSAID |
| Diclofenac | Common in MSK practice |
| Naproxen | Long-acting |
| Celecoxib | Selective COX-2 inhibitor; fewer GI effects but higher CV risk |
| Ketorolac | IV/IM; used for acute severe pain |
COX-1 vs COX-2 - Easy:
- COX-1 = "housekeeping" - protects stomach lining, helps platelets
- COX-2 = "inflammation" - activated by injury/disease
- Traditional NSAIDs block both → more GI side effects
- COX-2 inhibitors (celecoxib) = selective; less GI harm but more cardiovascular risk
Side effects:
| System | Effect |
|---|
| GI | Ulcers, bleeding, nausea |
| Renal | Reduced blood flow; renal impairment (avoid in renal disease) |
| Cardiovascular | Increased MI/stroke risk (especially COX-2 inhibitors) |
| Haematological | Impaired platelet function → bleeding risk |
Physio context: Tendinopathy, bursitis, acute sprains, arthritis flares, post-exercise DOMS.
PART 2 - OPIOID ANALGESICS
What are they?
Drugs that mimic natural endorphins by binding to opioid receptors in the brain, spinal cord, and periphery - blocking pain transmission.
Simple analogy: Opioid receptors are "locks," opioid drugs are "keys." When the key fits, pain signals are blocked.
Opioid Receptors
| Receptor | Location | Effect |
|---|
| Mu (μ) | Brain, spinal cord, gut | Analgesia, euphoria, respiratory depression, constipation |
| Kappa (κ) | Spinal cord | Analgesia, sedation, dysphoria |
| Delta (δ) | Brain | Analgesia, mood regulation |
Most opioids primarily act on the MU receptor.
Classification
Weak Opioids (Step 2)
| Drug | Key Facts |
|---|
| Codeine | Prodrug; converted to morphine in the liver; variable effect (genetics) |
| Tramadol | Weak mu-agonist + inhibits serotonin & norepinephrine reuptake (dual action); neuropathic + nociceptive pain |
| Tapentadol | Similar dual mechanism to tramadol; slightly stronger |
Strong Opioids (Step 3)
| Drug | Key Facts |
|---|
| Morphine | Gold standard; oral/IV/IM; active metabolites accumulate in renal failure |
| Oxycodone | Oral; commonly prescribed for moderate-severe pain |
| Fentanyl | 100x more potent than morphine; transdermal patch for chronic pain; IV in hospital |
| Buprenorphine | Partial mu-agonist; ceiling effect on respiratory depression; used in addiction + pain |
Mechanism of Opioids (Simple)
Opioid → binds mu receptor → opens K⁺ channels (hyperpolarization) → closes Ca²⁺ channels → blocks release of substance P and glutamate → pain signal is blocked at spinal cord and brain.
Side Effects - Mnemonic "CONS-RISE"
| Letter | Side Effect | Detail |
|---|
| C | Constipation | Most common; NO tolerance develops to this |
| O | Opioid respiratory depression | Most dangerous; dose-dependent; reversed by naloxone |
| N | Nausea/vomiting | Common especially at start |
| S | Sedation | Drowsiness, cognitive impairment |
| R | Retention (urinary) | Increased sphincter tone |
| I | Itching (pruritus) | Especially IV morphine |
| S | Seizures | High doses |
| E | Euphoria/Addiction | Especially with misuse |
Tolerance vs Dependence vs Addiction
| Term | Simple Meaning |
|---|
| Tolerance | Same dose = less effect over time; need higher dose |
| Physical dependence | Body adapts; stopping = withdrawal (sweating, tremors, anxiety) - NOT addiction |
| Addiction | Compulsive drug-seeking despite harm; psychological craving |
Reversal Agent
Naloxone: Pure mu-antagonist; rapidly reverses opioid overdose including respiratory depression; short-acting (may need repeat dosing).
PART 3 - ADJUVANT ANALGESICS
What are they?
Drugs originally developed for other conditions (depression, epilepsy) that also have significant pain-relieving effects - especially for neuropathic pain (nerve pain) and central sensitization.
Simple analogy: These are "helpers" - they boost the pain-relieving effect or work where opioids and NSAIDs fail.
A. Antidepressants
Tricyclic Antidepressants (TCAs)
- Examples: Amitriptyline, Nortriptyline
- Mechanism: Block reuptake of serotonin and norepinephrine → strengthen descending pain inhibitory pathways + sodium channel blockade
- Pain dose: Much lower than antidepressant dose (e.g., amitriptyline 10-75 mg at night)
- Used for: Neuropathic pain, fibromyalgia, migraine prevention, sleep disturbance in chronic pain
- Side effects: Sedation, dry mouth, constipation, urinary retention, cardiac arrhythmia - avoid in elderly
SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
- Examples: Duloxetine, Venlafaxine
- Mechanism: Inhibit reuptake of serotonin + norepinephrine → strengthen descending inhibition of pain
- Used for: Diabetic neuropathy, fibromyalgia, chronic low back pain, musculoskeletal pain
- Duloxetine is FDA-approved for diabetic peripheral neuropathy AND fibromyalgia
- EULAR recommends duloxetine for fibromyalgia
B. Anticonvulsants (Gabapentinoids)
| Drug | Dose Range | Key Use |
|---|
| Gabapentin | 300-3600 mg/day | Neuropathic pain, post-herpetic neuralgia, fibromyalgia |
| Pregabalin | 150-600 mg/day | Same as gabapentin but more predictable absorption; FDA-approved for fibromyalgia |
Mechanism: Bind to voltage-gated Ca²⁺ channels (α2δ subunit) in the dorsal horn → reduce release of excitatory neurotransmitters (glutamate, substance P) → reduce central sensitization.
Simple explanation: They "calm down" overexcited pain neurons in the spinal cord.
Side effects: Sedation, dizziness, weight gain, peripheral edema.
C. Corticosteroids
- Examples: Dexamethasone, Methylprednisolone, Triamcinolone
- Mechanism: Suppress phospholipase A2 and COX-2 → reduce prostaglandins, leukotrienes, histamine → powerful anti-inflammation
- Routes: Oral, IV, or local injection (intra-articular, peritendinous, epidural)
- Used for: Inflammatory arthritis flares, bursitis, tendinopathies, nerve root compression, cancer pain
- Local injection: Fewer systemic side effects; widely used in MSK physiotherapy practice
- Side effects (systemic/long-term): Osteoporosis, hyperglycemia, immunosuppression, adrenal suppression
D. Muscle Relaxants
- Examples: Cyclobenzaprine, Baclofen, Tizanidine, Methocarbamol
- Used for: Acute muscle spasm, spasticity (neurological causes)
- Recent evidence (2024): Systematic review found limited evidence supporting long-term use; associated with sedation and dependence risk [1]
E. Topical Analgesics
| Drug | Mechanism | Use |
|---|
| Topical NSAIDs (diclofenac gel) | Local COX inhibition | Knee OA, tendinopathy; minimal systemic absorption |
| Topical lidocaine (patches, gel) | Na⁺ channel blockade | Post-herpetic neuralgia, localized neuropathic pain |
| Capsaicin cream | Depletes substance P from nerve endings | OA, neuropathic pain |
PART 4 - LOCAL ANESTHETICS
What are they?
Drugs that completely block nerve conduction in a localized area - producing complete loss of sensation without affecting consciousness.
Simple analogy: Like turning off the electricity to one room of a house, leaving the rest of the house functioning normally.
Mechanism (Key Concept)
"The mechanism of action of local anesthetics is dose-dependent blockade of sodium currents in nerve fibers." - Sabiston Textbook of Surgery
Step by step:
- Drug enters the nerve axon
- Blocks voltage-gated Na⁺ channels (prevents Na⁺ influx)
- No Na⁺ influx = no action potential
- No action potential = no pain signal travels
Order of nerve blockade (smallest → largest fibers):
Pain (C and A-delta fibers) → Touch → Pressure → Motor fibers blocked last
Classification
By Chemical Structure
| Class | Examples | Metabolism |
|---|
| Esters | Procaine, Cocaine, Benzocaine, Tetracaine | Hydrolyzed in blood by pseudocholinesterase |
| Amides | Lidocaine, Bupivacaine, Ropivacaine, Mepivacaine | Metabolized in liver |
Memory trick: Amide names have the letter "i" before "caine" - lidocaine, bupivacaine, ropivacaine = "I am an amide"
By Duration
| Duration | Examples |
|---|
| Short (30-60 min) | Procaine, Lidocaine |
| Intermediate (2-4 hrs) | Mepivacaine |
| Long (4-12+ hrs) | Bupivacaine, Ropivacaine |
Key Drugs
| Drug | Key Points |
|---|
| Lidocaine | Prototype amide; intermediate duration; also an antiarrhythmic |
| Bupivacaine | Long-acting; cardiotoxic in IV overdose (severe arrhythmias, VF) |
| Ropivacaine | Similar to bupivacaine but less cardiotoxic; preferred for epidurals |
| Procaine | Old ester; historically first; replaced by lidocaine |
Routes Used in MSK / Physio Context
| Route | Use |
|---|
| Topical | Lidocaine patches; iontophoresis |
| Infiltration | Injection into painful soft tissue |
| Peripheral nerve block | Femoral nerve for knee; ankle block |
| Intra-articular injection | Knee joint post-op |
| Epidural / spinal | Surgical anesthesia; labor |
| Trigger point injection | Lidocaine into tender muscle trigger points |
Toxicity of Local Anesthetics
Occurs with accidental IV injection or overdose:
CNS (low dose): Tingling lips → Metallic taste → Tinnitus → Dizziness → Seizures
CVS (high dose): Bradycardia → Hypotension → Arrhythmias → Cardiac arrest (especially bupivacaine)
PART 5 - MULTIMODAL ANALGESIA
The modern gold-standard approach - using multiple drugs from different classes simultaneously, targeting different points in the pain pathway.
Why? Lower doses of each drug → fewer side effects, better overall pain control.
Standard multimodal regimen:
Paracetamol + NSAID/COX-2 inhibitor + Low-dose opioid (if needed) + Adjuvant (if neuropathic component) + Local anesthetic (regional or topical)
"Multimodal analgesia includes using multiple analgesic classes targeting different mechanisms to reduce opioid requirements and side effects." - Miller's Anesthesia, 10th Ed.
PART 6 - RECENT EVIDENCE PERTAINING TO PHYSIOTHERAPY
1. Early Physiotherapy Reduces Opioid Use
Patients who received early physiotherapy after shoulder, neck, low back, or knee pain were 7-16% less likely to use opioids in subsequent months. For those who did use opioids, early PT was associated with a 5-10% reduction in total opioid consumption. (Stanford/Duke University Study)
Clinical implication: Early physiotherapy referral is an evidence-based opioid prevention strategy.
2. Exercise Activates Endogenous Analgesia
Exercise activates the body's own pain-reducing systems:
- Endogenous opioid system (endorphins, enkephalins)
- Endocannabinoid system
- Serotonergic and noradrenergic descending inhibitory pathways
This produces exercise-induced hypoalgesia - pain threshold rises after exercise. Exercise is therefore a biological analgesic, not just a distraction.
Systematic review (2024) confirmed physical activity is effective for managing non-specific low back pain [2].
3. Non-Pharmacological Approaches Are First-Line (CDC & WHO)
Current clinical guideline reviews (2025) confirm that non-pharmacological approaches - including physiotherapy, exercise, and cognitive-behavioral therapy - should be used as first-line treatment for most chronic MSK pain. Opioids should only be considered when these have failed [3].
When opioids are prescribed, physiotherapy should run concurrently to support dose reduction.
4. Opioid Deprescribing and Physiotherapy
Clinical practice guideline (2023) recommends reducing opioid dose gradually (10% per week) while simultaneously increasing non-pharmacological support including physiotherapy and pain education [4].
A 2026 systematic review found that physical rehabilitation and pain self-management are among the strongest facilitators of successful opioid reduction in chronic non-cancer pain [5].
5. Exercise Therapy vs Manual Therapy for Chronic LBP
Systematic review with meta-analysis (2025) found both exercise therapy and manual therapy are equally effective for pain intensity, disability, and physical function in people with chronic low back pain [6]. This supports combining both approaches in clinical practice rather than choosing one over the other.
6. Non-Specific Effects of Physiotherapy on Pain
Meta-analysis (2024) found that a meaningful portion of physiotherapy's effect on MSK pain is due to contextual and non-specific factors (therapeutic relationship, patient expectations, environment) - reinforcing that effective pain management is always biopsychosocial, not just biological [7].
7. TENS as an Adjunct to Medications
Systematic review (2024) confirmed that TENS during functional activities or exercise is effective for pain relief, providing an evidence-based adjunct to pharmacological management - allowing lower drug doses and better participation in rehabilitation [8].
8. Drugs That Help Physiotherapy Work (Clinical Integration)
| Drug | How It Facilitates Physiotherapy |
|---|
| NSAIDs / Paracetamol | Pre-session dosing reduces pain enough to allow effective active exercise |
| Corticosteroid injection | Creates a window of reduced inflammation - ideal timing for intensive physio |
| Gabapentin/Pregabalin | Reduces central sensitization - makes patients more responsive to active rehab |
| Topical lidocaine/NSAIDs | Allows pain-free movement during exercise therapy |
| Local anesthetic block | Facilitates early mobility and physiotherapy post-operatively |
QUICK SUMMARY TABLE
| Category | Examples | Mechanism | Key Use | Key Side Effect |
|---|
| Paracetamol | Paracetamol | CNS COX inhibition | Mild-moderate pain | Hepatotoxicity in overdose |
| NSAIDs | Ibuprofen, Diclofenac, Celecoxib | COX-1+2 inhibition | Inflammation, MSK pain | GI ulcers, renal impairment |
| Weak opioids | Tramadol, Codeine | Mu-agonist ± SNRI | Moderate pain | Nausea, sedation |
| Strong opioids | Morphine, Fentanyl | Mu-receptor agonist | Severe pain | Respiratory depression, constipation |
| TCAs | Amitriptyline | SNRI + Na⁺ channel block | Neuropathic pain, fibromyalgia | Sedation, anticholinergic effects |
| SNRIs | Duloxetine | Serotonin + NE reuptake block | Neuropathic pain, fibromyalgia | Nausea, insomnia |
| Gabapentinoids | Gabapentin, Pregabalin | Ca²⁺ channel (α2δ) block | Neuropathic pain, central sensitization | Sedation, dizziness |
| Corticosteroids | Dexamethasone, Triamcinolone | Anti-inflammatory | Flares, injections | Osteoporosis, hyperglycemia |
| Local anesthetics | Lidocaine, Bupivacaine | Na⁺ channel blockade | Nerve blocks, topical, injections | CNS/CVS toxicity (IV overdose) |
EXAM RAPID-FIRE POINTS
- WHO ladder: Step 1 = Non-opioids → Step 2 = Weak opioids → Step 3 = Strong opioids
- Paracetamol = pain + fever only; NOT anti-inflammatory
- NSAIDs = pain + fever + inflammation; risk = GI ulcers, renal failure
- All opioids act on Mu receptor; naloxone reverses overdose
- Tramadol = weak opioid + SNRI mechanism (dual action)
- Respiratory depression = most dangerous opioid side effect; reversed by naloxone
- Constipation = most consistent opioid side effect; no tolerance develops
- Gabapentin/Pregabalin = block Ca²⁺ channels; reduce central sensitization
- Duloxetine = FDA-approved for diabetic neuropathy AND fibromyalgia
- Local anesthetics = block Na⁺ channels; pain fibers blocked first, motor last
- Bupivacaine = long-acting but highly cardiotoxic in IV overdose
- Esters metabolized in blood; Amides metabolized in liver
- Early physiotherapy reduces opioid use by 7-16%
- Exercise = biological analgesic via endorphin + endocannabinoid + serotonin systems
- CDC guidelines: Non-pharmacological approaches (including PT) = FIRST LINE for chronic MSK pain
REFERENCES (Vancouver Style)
-
Oldfield BJ, Gleeson B, Morford KL, Adams Z, Funaro MC, Becker WC. Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review. JAMA Netw Open. 2024 Sep 3;7(9):e2434835. doi: 10.1001/jamanetworkopen.2024.34835. PMID: 39298168.
-
Alonso-Sal A, Alonso-Perez JL, Sosa-Reina MD, García-Noblejas-Fernández JA, Balani-Balani VG, Rossettini G. Effectiveness of Physical Activity in the Management of Nonspecific Low Back Pain: A Systematic Review. Medicina (Kaunas). 2024 Dec 16;60(12):2065. doi: 10.3390/medicina60122065. PMID: 39768944.
-
Mazurenko O, O'Brien E, Beug A, Smith SM, McCarthy C. Recommendations for managing adults with chronic non-cancer pain in primary care: A systematic clinical guideline review. J Eval Clin Pract. 2025 Feb;31(1):e14118. doi: 10.1111/jep.14118. PMID: 39104080.
-
Langford AV, Lin CC, Bero L, Blyth FM, Doctor J, Holliday S. Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust. 2023 Jul 17;219(2):64-70. doi: 10.5694/mja2.52002. PMID: 37356051.
-
Marcelo AC, Hilmer SN, Hunter DJ, Mathieson S, Mohamed R, Li L. Patient- and Clinician-Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non-Cancer Pain: A Systematic Review. Clin Pharmacol Ther. 2026 Jul;120(1):89-107. doi: 10.1002/cpt.70254. PMID: 41813618.
-
González-Gómez L, Moral-Munoz JA, Rosales-Tristancho A, Cuevas-Moreno A, Cardellat-González M, Rodríguez-Domínguez AJ. Exercise Therapy Versus Manual Therapy for the Management of Pain Intensity, Disability, and Physical Function in People With Chronic Low Back Pain: A Systematic Review With Meta-Analysis and Meta-Regression. Eur J Pain. 2025 Sep;29(7):e70090. doi: 10.1002/ejp.70090. PMID: 40747709.
-
Ezzatvar Y, Dueñas L, Balasch-Bernat M, Lluch-Girbés E, Rossettini G. Which Portion of Physiotherapy Treatments' Effect Is Not Attributable to the Specific Effects in People With Musculoskeletal Pain? A Meta-Analysis of Randomized Placebo-Controlled Trials. J Orthop Sports Phys Ther. 2024 Jun;54(6):1-13. doi: 10.2519/jospt.2024.12126. PMID: 38602164.
-
de Espíndula Brehm T, Pang Bilby AS, Guizzo KZ, Marcolino AM, Kuriki HU, Barbosa RI. Effects of Transcutaneous Electrical Nerve Stimulation (TENS) During Functional Activities or Exercise: A Systematic Review. Musculoskelet Care. 2024 Dec;22(4):e70020. doi: 10.1002/msc.70020. PMID: 39592440.